On May 14, 2020 MEI Pharma, Inc. (NASDAQ: MEIP), a late-stage pharmaceutical company focused on advancing new therapies for cancer, and Kyowa Kirin Co., Ltd. (Kyowa Kirin, TSE: 4151), a global specialty pharmaceutical company creating innovative medical solutions utilizing the latest biotechnology, reported that updated Phase 1b data on ME-401, its investigational oral phosphatidylinositol 3-kinase delta (PI3Kδ) inhibitor drug-candidate in clinical development for the treatment of follicular lymphoma and other B-cell malignancies, will be presented in a poster session at the Virtual Edition of the 25th European Hematology Association (EHA) (Free EHA Whitepaper) Annual Congress to be held June 11 to June 14, 2020 (Press release, MEI Pharma, MAY 14, 2020, View Source [SID1234558033]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Presentation at EHA (Free EHA Whitepaper)25 Virtual Congress

Title: The PI3kδ Inhibitor ME-401 is Well-Tolerated on Intermittent Schedule and Produces a High-Rate of Durable Responses in Relapsed Refractory (R/R) Indolent B-Cell Malignancies
Session Title: Indolent and mantle-cell non-Hodgkin lymphoma – Clinical
Authors: John Pagel, et. al.
Abstract ID: EP1174
Session Type: Poster

The abstract is available on the EHA (Free EHA Whitepaper) Annual Congress website. Presentations and posters will be available on the EHA (Free EHA Whitepaper) website for on-demand viewing beginning on June 12, 2020 at 8:30 a.m. ET.